NASDAQ:FATE - Fate Therapeutics Stock Price, Price Target & More

$11.93 +0.50 (+4.37 %)
(As of 04/26/2018 11:18 AM ET)
Previous Close$11.43
Today's Range$11.48 - $12.35
52-Week Range$2.52 - $14.45
Volume647,149 shs
Average Volume695,470 shs
Market Capitalization$594.21 million
P/E Ratio-11.75
Dividend YieldN/A
Beta1.74

About Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics logoFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

Receive FATE News and Ratings via Email

Sign-up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FATE
CUSIPN/A
Phone858-875-1800

Debt

Debt-to-Equity Ratio0.19%
Current Ratio9.29%
Quick Ratio9.29%

Price-To-Earnings

Trailing P/E Ratio-11.75
Forward P/E Ratio-12.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.11 million
Price / Sales153.17
Cash FlowN/A
Price / CashN/A
Book Value$1.51 per share
Price / Book7.90

Profitability

EPS (Most Recent Fiscal Year)($1.02)
Net Income$-42,950,000.00
Net Margins-1,046.08%
Return on Equity-71.00%
Return on Assets-50.95%

Miscellaneous

Employees80
Outstanding Shares52,770,000

How to Become a New Pot Stock Millionaire

Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics (NASDAQ:FATE) issued its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.05. The biopharmaceutical company earned $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. Fate Therapeutics's revenue was up .0% on a year-over-year basis. View Fate Therapeutics' Earnings History.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Fate Therapeutics.

What price target have analysts set for FATE?

8 brokers have issued twelve-month price targets for Fate Therapeutics' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Fate Therapeutics' stock price to reach $16.1667 in the next twelve months. View Analyst Ratings for Fate Therapeutics.

What are Wall Street analysts saying about Fate Therapeutics stock?

Here are some recent quotes from research analysts about Fate Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Fate Announces Updated Data From Phase 1 of PROTECT; Reiterate Neutral Updated ProTmune data shows continued safety and efficacy. Yesterday, Fate Therapeutics announced additional Phase 1 clinical data from PROTECT. As a reminder, Fate is investigating ProTmune, a next-generation hematopoietic cell graft for the prevention of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Data reported at ASH indicated that all subjects (n=7) remained relapse-free, and there were no events of graft failure or serious adverse events (SAEs) that were deemed related to ProTmune. In the study, three out of seven subjects experienced acute GvHD in the first 100 days. However, all subjects responded to standard-of care steroid treatment, and all three cases of GvHD resolved within 5-8 days." (3/20/2018)
  • 2. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (3/7/2018)

Are investors shorting Fate Therapeutics?

Fate Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totalling 3,401,562 shares, an increase of 47.8% from the February 28th total of 2,301,328 shares. Based on an average trading volume of 1,116,342 shares, the days-to-cover ratio is presently 3.0 days. Currently, 7.6% of the shares of the stock are short sold.

Who are some of Fate Therapeutics' key competitors?

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the folowing people:
  • Mr. J. Scott Wolchko, Founder, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 48)
  • Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 50)
  • Dr. Stewart Abbot, Chief Devel. Officer (Age 51)
  • Dr. Michael Rudnicki Ph.D., Co-Founder
  • Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 45)

Has Fate Therapeutics been receiving favorable news coverage?

News coverage about FATE stock has been trending positive recently, Accern reports. Accern identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fate Therapeutics earned a media sentiment score of 0.39 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 47.17 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Fate Therapeutics?

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $12.10.

How big of a company is Fate Therapeutics?

Fate Therapeutics has a market capitalization of $594.21 million and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]


MarketBeat Community Rating for Fate Therapeutics (FATE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fate Therapeutics (NASDAQ:FATE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Fate Therapeutics in the last 12 months. Their average twelve-month price target is $16.1667, suggesting that the stock has a possible upside of 35.51%. The high price target for FATE is $20.00 and the low price target for FATE is $7.00. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.883.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.1667$14.6667$7.6667$7.20
Price Target Upside: 35.51% upside25.14% upside10.15% upside75.18% upside

Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History

Price Target History for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018WedbushReiterated RatingOutperform$19.00LowView Rating Details
3/20/2018HC WainwrightReiterated RatingHold$12.00MediumView Rating Details
3/6/2018UBSDowngradeOutperform -> Market PerformHighView Rating Details
3/6/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$7.00 -> $20.00HighView Rating Details
3/6/2018Wells FargoReiterated RatingOutperform$10.00 -> $19.00HighView Rating Details
3/6/2018Piper JaffrayReiterated RatingOverweight -> Top Pick$20.00HighView Rating Details
12/12/2017Raymond JamesReiterated RatingBuyMediumView Rating Details
9/8/2017Leerink SwannReiterated RatingOutperform -> Outperform$7.00MediumView Rating Details
3/18/2017Roth CapitalSet Price TargetBuy$8.00LowView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Fate Therapeutics (NASDAQ:FATE) Earnings History and Estimates Chart

Earnings by Quarter for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ:FATE) Earnings Estimates

2018 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.22)($0.17)($0.20)
Q2 20182($0.25)($0.22)($0.24)
Q3 20182($0.24)($0.22)($0.23)
Q4 20182($0.23)($0.21)($0.22)

Fate Therapeutics (NASDAQ FATE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018($0.23)N/AView Earnings Details
3/5/2018Q4 2017($0.24)($0.29)$1.02 million$1.03 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.25)($0.26)$0.95 million$1.03 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.2360)($0.23)$1.02 million$1.03 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.21)($0.24)$1.04 million$1.03 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.2830)($0.21)$1.06 million$1.03 millionViewN/AView Earnings Details
11/7/2016Q316($0.29)($0.27)$1.05 million$1.03 millionViewListenView Earnings Details
8/8/2016Q216($0.32)($0.29)$1.02 million$1.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.25)($0.29)$0.84 million$1.32 millionViewN/AView Earnings Details
3/3/2016Q415($0.27)($0.26)$0.58 million$1.08 millionViewN/AView Earnings Details
11/3/2015Q315($0.32)($0.24)$0.46 million$1.03 millionViewN/AView Earnings Details
8/5/2015Q215($0.39)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
5/7/2015Q115($0.34)($0.38)ViewListenView Earnings Details
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details
11/11/2014Q3 2014($0.29)($0.30)ViewN/AView Earnings Details
8/12/2014Q214($0.36)($0.30)ViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.34)ViewN/AView Earnings Details
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details
11/13/2013Q3($0.32)($4.81)$0.21 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Fate Therapeutics (NASDAQ:FATE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Fate Therapeutics (NASDAQ FATE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.89%
Institutional Ownership Percentage: 66.45%
Insider Trading History for Fate Therapeutics (NASDAQ:FATE)
Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics (NASDAQ FATE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/16/2017Cindy TahlGeneral CounselSell8,091$3.85$31,150.35View SEC Filing  
10/16/2017Daniel D ShoemakerInsiderSell13,225$3.87$51,180.75View SEC Filing  
11/23/2016Chris StorgardInsiderBuy37,593$2.66$99,997.389,090View SEC Filing  
11/23/2016William H RastetterDirectorBuy375,939$2.66$999,997.74View SEC Filing  
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fate Therapeutics (NASDAQ FATE) News Headlines

Source:
DateHeadline
$2.02 Million in Sales Expected for Fate Therapeutics (FATE) This Quarter$2.02 Million in Sales Expected for Fate Therapeutics (FATE) This Quarter
www.americanbankingnews.com - April 23 at 3:00 AM
-$0.22 EPS Expected for Fate Therapeutics (FATE) This Quarter-$0.22 EPS Expected for Fate Therapeutics (FATE) This Quarter
www.americanbankingnews.com - April 21 at 3:22 PM
Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual ...Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual ...
globenewswire.com - April 18 at 5:45 PM
Fate Therapeutics (FATE) Given Consensus Recommendation of "Buy" by BrokeragesFate Therapeutics (FATE) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 14 at 1:25 AM
Stock Traders Purchase Large Volume of Call Options on Fate Therapeutics (FATE)Stock Traders Purchase Large Volume of Call Options on Fate Therapeutics (FATE)
www.americanbankingnews.com - April 13 at 6:56 AM
Fate Therapeutics Inc’s (NASDAQ:FATE) Shift From Loss To ProfitFate Therapeutics Inc’s (NASDAQ:FATE) Shift From Loss To Profit
finance.yahoo.com - April 10 at 5:29 PM
$2.34 Million in Sales Expected for Fate Therapeutics (FATE) This Quarter$2.34 Million in Sales Expected for Fate Therapeutics (FATE) This Quarter
www.americanbankingnews.com - April 6 at 2:50 AM
Fate Therapeutics (FATE) Expected to Announce Earnings of -$0.22 Per ShareFate Therapeutics (FATE) Expected to Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - April 4 at 3:14 PM
Fate Therapeutics (FATE) Lifted to Buy at ValuEngineFate Therapeutics (FATE) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM
Wired News - Fate Therapeutics Presented Positive Clinical Data of FATE-NK100s APOLLO Phase-1 Study in Recurrent Ovarian Cancer at the Innate Killer Summit 2018Wired News - Fate Therapeutics Presented Positive Clinical Data of FATE-NK100's APOLLO Phase-1 Study in Recurrent Ovarian Cancer at the Innate Killer Summit 2018
finance.yahoo.com - April 3 at 8:24 AM
3 Things In Biotech, April 1: Fates Omens, Mallinckrodts Trial, Insmeds Journey3 Things In Biotech, April 1: Fate's Omens, Mallinckrodt's Trial, Insmed's Journey
seekingalpha.com - April 2 at 8:40 AM
Fate Therapeutics (FATE) Buy Rating Reiterated at BMO Capital MarketsFate Therapeutics' (FATE) Buy Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - April 2 at 8:20 AM
Fate Therapeutics (FATE) Receives Buy Rating from HC WainwrightFate Therapeutics (FATE) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - April 1 at 11:24 PM
Fate Therapeutics (FATE) Raised to Hold at ValuEngineFate Therapeutics (FATE) Raised to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:06 PM
Edited Transcript of FATE earnings conference call or presentation 1-Nov-17 9:00pm GMTEdited Transcript of FATE earnings conference call or presentation 1-Nov-17 9:00pm GMT
finance.yahoo.com - March 30 at 5:30 PM
Fate Therapeutics (FATE) Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian CancerFate Therapeutics (FATE) Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer
www.streetinsider.com - March 30 at 8:23 AM
Short Interest in Fate Therapeutics (FATE) Grows By 47.8%Short Interest in Fate Therapeutics (FATE) Grows By 47.8%
www.americanbankingnews.com - March 30 at 3:38 AM
Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer ...Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer ...
globenewswire.com - March 29 at 5:30 PM
Fate Therapeutics (FATE) Outperform Rating Reaffirmed at WedbushFate Therapeutics' (FATE) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 29 at 4:10 PM
Fate Therapeutics FATE-NK100 shows encouraging action in early-stage ovarian cancer study; shares ahead 5% premarketFate Therapeutics' FATE-NK100 shows encouraging action in early-stage ovarian cancer study; shares ahead 5% premarket
seekingalpha.com - March 29 at 9:16 AM
Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018
finance.yahoo.com - March 29 at 8:28 AM
Fate Therapeutics (FATE) Downgraded by Zacks Investment Research to HoldFate Therapeutics (FATE) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 28 at 6:00 PM
Edited Transcript of FATE earnings conference call or presentation 5-Mar-18 10:00pm GMTEdited Transcript of FATE earnings conference call or presentation 5-Mar-18 10:00pm GMT
finance.yahoo.com - March 27 at 5:14 PM
Fate Therapeutics (FATE) Rating Increased to Strong-Buy at BidaskClubFate Therapeutics (FATE) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 26 at 11:30 PM
Fate Therapeutics (FATE) Rating Reiterated by Piper Jaffray CompaniesFate Therapeutics (FATE) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - March 24 at 11:24 AM
Fate Therapeutics (FATE) Reports Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmuneFate Therapeutics (FATE) Reports Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune
www.streetinsider.com - March 21 at 5:38 PM
Fate Therapeutics (FATE) Stock Rating Reaffirmed by HC WainwrightFate Therapeutics (FATE) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - March 20 at 11:56 AM
Zacks: Brokerages Anticipate Fate Therapeutics Inc (FATE) Will Announce Quarterly Sales of $2.01 MillionZacks: Brokerages Anticipate Fate Therapeutics Inc (FATE) Will Announce Quarterly Sales of $2.01 Million
www.americanbankingnews.com - March 20 at 4:29 AM
Fate Therapeutics Inc (FATE) Receives Consensus Recommendation of "Buy" from AnalystsFate Therapeutics Inc (FATE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 20 at 1:46 AM
Innovest Global Inc. Signs Letter of Intent to Acquire 20% of StemVax Therapeutics, a Biotechnology & Health Sciences CompanyInnovest Global Inc. Signs Letter of Intent to Acquire 20% of StemVax Therapeutics, a Biotechnology & Health Sciences Company
finance.yahoo.com - March 19 at 5:18 PM
Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™ - GlobeNewswire (press release)Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™ - GlobeNewswire (press release)
globenewswire.com - March 19 at 8:22 AM
Fate Therapeutics (FATE) Reports Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune - StreetInsider.comFate Therapeutics (FATE) Reports Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune - StreetInsider.com
www.streetinsider.com - March 19 at 8:22 AM
Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™
finance.yahoo.com - March 19 at 8:22 AM
Wired News – CTI BioPharma’s Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA OncologyWired News – CTI BioPharma’s Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology
finance.yahoo.com - March 13 at 8:25 AM
Short Interest in Fate Therapeutics Inc (FATE) Expands By 28.7%Short Interest in Fate Therapeutics Inc (FATE) Expands By 28.7%
www.americanbankingnews.com - March 13 at 1:09 AM
Leerink Swann Comments on Fate Therapeutics Incs FY2018 Earnings (FATE)Leerink Swann Comments on Fate Therapeutics Inc's FY2018 Earnings (FATE)
www.americanbankingnews.com - March 8 at 9:09 AM
Fate Therapeutics Inc (FATE) Forecasted to Earn Q1 2018 Earnings of ($0.17) Per ShareFate Therapeutics Inc (FATE) Forecasted to Earn Q1 2018 Earnings of ($0.17) Per Share
www.americanbankingnews.com - March 8 at 6:28 AM
Zacks Investment Research Lowers Fate Therapeutics (FATE) to SellZacks Investment Research Lowers Fate Therapeutics (FATE) to Sell
www.americanbankingnews.com - March 7 at 11:22 PM
Fate Therapeutics Inc (FATE) to Post FY2021 Earnings of $1.61 Per Share, Wedbush ForecastsFate Therapeutics Inc (FATE) to Post FY2021 Earnings of $1.61 Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 7 at 4:21 PM
Analysts Offer Predictions for Fate Therapeutics Incs Q1 2018 Earnings (FATE)Analysts Offer Predictions for Fate Therapeutics Inc's Q1 2018 Earnings (FATE)
www.americanbankingnews.com - March 7 at 7:54 AM
Fate Therapeutics (FATE) Rating Lowered to Neutral at HC WainwrightFate Therapeutics (FATE) Rating Lowered to Neutral at HC Wainwright
www.americanbankingnews.com - March 6 at 10:20 PM
BMO Capital Markets Increases Fate Therapeutics (FATE) Price Target to $20.00BMO Capital Markets Increases Fate Therapeutics (FATE) Price Target to $20.00
www.americanbankingnews.com - March 6 at 10:20 PM
Fate Therapeutics (FATE) Given "Outperform" Rating at WedbushFate Therapeutics (FATE) Given "Outperform" Rating at Wedbush
www.americanbankingnews.com - March 6 at 2:17 PM
Fate Therapeutics (FATE) Outperform Rating Reiterated at Wells Fargo & CoFate Therapeutics' (FATE) Outperform Rating Reiterated at Wells Fargo & Co
www.americanbankingnews.com - March 6 at 1:16 PM
Fate Therapeutics (FATE) Lowered to "Market Perform" at UBS GroupFate Therapeutics (FATE) Lowered to "Market Perform" at UBS Group
www.americanbankingnews.com - March 6 at 8:42 AM
Fate Therapeutics (FATE) PT Raised to $18 at Wells Fargo - StreetInsider.comFate Therapeutics (FATE) PT Raised to $18 at Wells Fargo - StreetInsider.com
www.streetinsider.com - March 6 at 8:15 AM
Fate Therapeutics (FATE) CEO Scott Wolchko on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaFate Therapeutics' (FATE) CEO Scott Wolchko on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 6 at 8:15 AM
Fate Therapeutics Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)Fate Therapeutics Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:15 AM
Fate Therapeutics (FATE) Announces Quarterly  Earnings Results, Misses Expectations By $0.04 EPSFate Therapeutics (FATE) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - March 5 at 9:14 PM
Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational ProgressFate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress
finance.yahoo.com - March 5 at 5:50 PM

SEC Filings

Fate Therapeutics (NASDAQ:FATE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fate Therapeutics (NASDAQ:FATE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fate Therapeutics (NASDAQ FATE) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.